These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 12572580)

  • 1. Aspirin, clopidogrel, or both for secondary prevention of coronary disease.
    de Lemos JA; McGuire DK
    N Engl J Med; 2003 Feb; 348(6):560-3; author reply 560-3. PubMed ID: 12572580
    [No Abstract]   [Full Text] [Related]  

  • 2. Aspirin, clopidogrel, or both for secondary prevention of coronary disease.
    Armstrong EC
    N Engl J Med; 2003 Feb; 348(6):560-3; author reply 560-3. PubMed ID: 12572582
    [No Abstract]   [Full Text] [Related]  

  • 3. Aspirin, clopidogrel, or both for secondary prevention of coronary disease.
    Yaes RJ
    N Engl J Med; 2003 Feb; 348(6):560-3; author reply 560-3. PubMed ID: 12572584
    [No Abstract]   [Full Text] [Related]  

  • 4. Aspirin, clopidogrel, or both for secondary prevention of coronary disease.
    Akinlade BK
    N Engl J Med; 2003 Feb; 348(6):560-3; author reply 560-3. PubMed ID: 12571267
    [No Abstract]   [Full Text] [Related]  

  • 5. Aspirin, clopidogrel, or both for secondary prevention of coronary disease.
    Ramsey SD
    N Engl J Med; 2003 Feb; 348(6):560-3; author reply 560-3. PubMed ID: 12572583
    [No Abstract]   [Full Text] [Related]  

  • 6. Clopidogrel in acute coronary syndromes: can the cost effectiveness improve?
    Sánchez-Delgado E
    Circulation; 2003 Aug; 108(8):e56; author reply e56. PubMed ID: 12939246
    [No Abstract]   [Full Text] [Related]  

  • 7. When increased therapeutic benefit comes at increased cost.
    Wood AJ
    N Engl J Med; 2002 Jun; 346(23):1819-21. PubMed ID: 12050345
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clopidogrel--an expensive thrombocyte inhibitor with a small marginal benefit].
    Asplund K
    Lakartidningen; 2000 Mar; 97(11):1294-6. PubMed ID: 10771550
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.
    Gaspoz JM; Coxson PG; Goldman PA; Williams LW; Kuntz KM; Hunink MG; Goldman L
    N Engl J Med; 2002 Jun; 346(23):1800-6. PubMed ID: 12050341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness.
    Ho WK; Hankey GJ; Eikelboom JW
    Expert Opin Pharmacother; 2004 Mar; 5(3):493-503. PubMed ID: 15013918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clopidogrel versus aspirin and esomeprazole to prevent recurrent bleeding.
    Barski PR
    N Engl J Med; 2005 Apr; 352(16):1716-8; author reply 1716-8. PubMed ID: 15846857
    [No Abstract]   [Full Text] [Related]  

  • 12. [Acute coronary syndrome. The second platelet inhibitor is self-paid].
    MMW Fortschr Med; 2003 Jun; 145(24):52. PubMed ID: 12866304
    [No Abstract]   [Full Text] [Related]  

  • 13. Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2006; 24(7):709-26. PubMed ID: 16802846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifibrinolytics may be cost saving among recent recipients of combined acetylsalicylic acid and clopidogrel who undergo coronary artery bypass graft surgery.
    Ray JG; Hamielec CM
    Can J Cardiol; 2004 Jun; 20(8):829-30. PubMed ID: 15229768
    [No Abstract]   [Full Text] [Related]  

  • 15. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
    Lindgren P; Stenestrand U; Malmberg K; Jönsson B
    Clin Ther; 2005 Jan; 27(1):100-10. PubMed ID: 15763611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark].
    Heeg B; van Gestel A; Hout Bv; Olsen J; Haghfelt TH
    Ugeskr Laeger; 2006 Aug; 168(35):2911-5. PubMed ID: 16982022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Counting the true cost of antiplatelet therapy for stroke prevention.
    Morton JA; Newton J; Gray CS
    Age Ageing; 2005 May; 34(3):212-4. PubMed ID: 15863405
    [No Abstract]   [Full Text] [Related]  

  • 19. Antiplatelet therapy for ischemic heart disease.
    Steimle AE
    N Engl J Med; 2004 May; 350(20):2101-2; author reply 2101-2. PubMed ID: 15141055
    [No Abstract]   [Full Text] [Related]  

  • 20. Aspirin desensitization in patients with coronary artery disease: Cost savings.
    Cubero JL; Simó Sánchez B; Millán P; Colás C
    Med Intensiva; 2017 Oct; 41(7):446-447. PubMed ID: 28196671
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.